Epizyme (EPZM) Misses Q3 EPS by 16c

Epizyme (NASDAQ: EPZM) reported Q3 EPS of ($0.64), $0.16 worse than the analyst estimate of ($0.48). Revenue for the quarter came in at $5.2 million versus the consensus estimate of $13.18 million.

For earnings history and earnings-related data on Epizyme (EPZM) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
• Bernstein remains bullish on SpaceX but sees challenges in telecom ambitions